证券代码：688505 证券简称：复旦张江 编号：临 2026-006 上海复旦张江生物医药股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载 2025 年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以上海复旦张江生物医药股份有限公司（以下简称"公司"）2025 年年度报告中披露的数据为准，提请投资者注意投资风险。 一、 2025 年度主要财务数据和指标 单位：人民币元 | 项 目 | 本报告期 | 上年同期 | 增减变动幅度（％） | | --- | --- | --- | --- | | 营业总收入 | 685,797,316 | 709,404,966 | -3.33 | | 营业利润 | -155,402,230 | 2,393,845 | -6,591.74 | | 利润总额 | -155,851,308 | 5,457,930 | -2,955.50 | | 归属于母公司所有者的净利润 | -157,439,498 | 39,733,896 | ...

Financial Performance - Total operating revenue for 2025 reached CNY 154,115.64 million, a year-on-year increase of 9.54%[4] - Net profit attributable to shareholders of the parent company was CNY 15,944.12 million, representing a significant increase of 406.47% compared to the previous year[4] - Operating profit rose to CNY 17,183.37 million, marking a 171.89% increase year-on-year[4] - The basic earnings per share increased to CNY 0.81, up 406.25% from CNY 0.16 in the previous year[4] - The net profit after deducting non-recurring gains and losses was CNY 5,970.62 million, a 69.36% increase year-on-year[4] Asset and Return Metrics - Total assets at the end of the reporting period were CNY 354,408.60 million, reflecting a 12.08% increase from the beginning of the period[4] - The weighted average return on net assets improved to 9.47%, an increase of 7.53 percentage points compared to the previous year[4] Revenue Sources - The company achieved strong growth in overseas revenue, contributing to the overall increase in operating income[7] Non-Recurring Items - Non-recurring gains and losses increased significantly due to changes in the fair value of private equity funds held by the company[7] - The company has not yet obtained the audit report for its private equity fund, which may impact the final net profit figures[8]

Financial Performance - Total revenue for 2025 reached RMB 5,928,744,673.06, a year-on-year increase of 15.78%[4] - Net profit attributable to shareholders of the parent company was RMB 1,842,976,801.74, up 12.03% compared to the previous year[4] - Net profit excluding non-recurring gains and losses was RMB 1,807,693,940.69, reflecting a growth of 16.15% year-on-year[4] - Basic earnings per share increased to RMB 3.98, representing an 11.80% rise compared to the previous year[4] Revenue Breakdown - WPS personal business revenue was approximately RMB 3,626 million, increasing by 10.42% year-on-year[6] - WPS 365 business revenue surged to approximately RMB 720 million, a remarkable growth of 64.93%[6] - WPS software business revenue reached approximately RMB 1,461 million, up 15.24% year-on-year[6] Assets and Equity - Total assets at the end of the reporting period were RMB 18,159,187,943.65, a 14.12% increase from the beginning of the period[4] - Shareholders' equity attributable to the parent company was RMB 12,859,947,253.44, reflecting a growth of 13.25%[4] Product Development - The company continues to enhance its AI office capabilities with the upgraded WPS AI 3.0 and WPS 365 products, solidifying its market position[6]

Financial Performance - Total revenue for 2025 reached RMB 74,568.01 million, a 57.33% increase compared to RMB 47,396.77 million in the same period last year[4] - Net profit attributable to shareholders of the parent company was RMB 3,539.09 million, marking a turnaround from a loss of RMB 110,298.83 million in the previous year[4] - The weighted average return on equity increased by 96.32 percentage points to 5.29% from -91.03% in the previous year[4] - Basic earnings per share improved to RMB 0.20 from a loss of RMB 6.27 per share in the previous year[4] Assets and Equity - Total assets at the end of the reporting period were RMB 231,184.94 million, a decrease of 22.45% from RMB 298,093.54 million at the beginning of the period[4] - Shareholders' equity attributable to the parent company increased by 4.84% to RMB 68,232.32 million from RMB 65,084.86 million at the beginning of the period[4] Strategic Focus and Operational Efficiency - The company focused on strategic adjustments in its business structure, concentrating resources on the automotive equipment sector, which contributed to revenue growth[6] - The sales gross margin significantly increased due to prioritizing high-margin quality clients, enhancing overall profitability[7] - Cost control measures and efficiency improvements led to a reduction in operating expenses, positively impacting profit growth[8] - The company reported good cash collection, resulting in a reversal of credit impairment losses[8]

Financial Performance - Total operating revenue for 2025 reached RMB 944.90 million, an increase of 6.55% compared to RMB 886.78 million in the previous year[3] - Net profit attributable to shareholders of the parent company was RMB 119.12 million, up 5.89% from RMB 112.49 million year-on-year[3] - Net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses surged by 291.23% to RMB 81.22 million from RMB 20.76 million[3] - The company reported a basic earnings per share of RMB 0.10, reflecting a 5.89% increase from RMB 0.09 in the previous year[3] - The weighted average return on net assets increased by 0.06 percentage points to 1.31%[3] - The company's equity attributable to shareholders of the parent company was RMB 901.61 million, a slight increase of 0.28% from RMB 899.09 million[3] Assets and Subsidiaries - Total assets at the end of the reporting period amounted to RMB 1,669.79 million, a 4.73% increase from RMB 1,594.36 million at the beginning of the period[3] - The company established a wholly-owned subsidiary, Guangzhou Ruisheng Robot Technology Co., Ltd., focusing on high-precision and high-speed six-axis robots and related technologies[5] Market Expansion and Strategy - The company is actively expanding its market presence both domestically and internationally, with positive developments in its digital technology and intelligent manufacturing sectors[5] - The significant increase in net profit after deducting non-recurring gains and losses was primarily due to revenue growth and a reduction in impairment provisions[6]

Financial Performance - The total operating revenue for 2025 reached ¥806.82 million, an increase of 42.23% compared to the previous year[3] - The net profit attributable to the parent company was ¥143.12 million, reflecting a growth of 101.89% year-on-year[3] - The net profit attributable to the parent company after deducting non-recurring gains and losses was ¥137.99 million, up 141.34% from the previous year[3] - Basic earnings per share increased to ¥0.4456, a rise of 100.99% compared to the same period last year[3] Assets and Equity - The total assets at the end of the reporting period were ¥2,332.17 million, a 15.94% increase from the beginning of the period[5] - The equity attributable to the parent company was ¥1,776.18 million, growing by 5.28% from the start of the period[5] Profitability and Market Position - The gross profit margin improved due to a decrease in unit fixed costs as production volume increased, enhancing overall profitability[5] - The company maintained its position as a leading domestic blood purification equipment manufacturer, benefiting from technological advantages and strong brand effects[6] - The sales revenue of self-produced blood purification consumables significantly increased during the reporting period[6] Reporting Accuracy - There are no major uncertainties affecting the accuracy of the performance report as of the announcement date[7]

Financial Performance - The company achieved total operating revenue of 68,920.03 million yuan, an increase of 45.22% compared to the same period last year [2]. - The net profit attributable to the parent company was -2,137.40 million yuan, a decline from -197.40 million yuan in the previous year [2]. - Operating profit decreased to -2,153.09 million yuan, down 450.59% year-on-year [2]. - Basic earnings per share decreased to -0.16 yuan, reflecting the decline in net profit [2]. - Financial expenses increased due to higher bank borrowing and exchange rate fluctuations, impacting overall profitability [8]. Growth Strategy - The company is focusing on markets such as AI high-speed connectors, optical modules, server power supplies, and automotive electronics for future growth [6]. - The company plans to accelerate overseas market expansion and increase the share of large customer orders to optimize capacity utilization [6]. - The company is enhancing its online mall operations to improve the PCB prototyping experience and achieve scalable growth [6]. Capacity and Assets - The company is experiencing a capacity ramp-up phase, leading to high fixed costs and increased impairment losses [7]. - Total assets at the end of the reporting period were 143,920.59 million yuan, an increase of 26.08% from the beginning of the period [2].

Revenue Performance - Total revenue for 2025 was RMB 39,184,218,359.14, a decrease of 3.79% compared to RMB 40,726,522,046.23 in the previous year[4] Profitability - Operating profit increased by 6.25% to RMB 3,838,353,877.00 from RMB 3,612,644,570.29 year-on-year[4] - Total profit rose by 7.01% to RMB 3,832,852,450.72, up from RMB 3,581,933,851.05 in the previous year[4] - Net profit attributable to shareholders increased by 5.05% to RMB 3,257,857,931.51 from RMB 3,101,256,409.22 year-on-year[4] - Basic earnings per share improved by 5.06% to RMB 1.1658 compared to RMB 1.1097 in the previous year[4] Assets and Equity - Total assets at the end of the reporting period were RMB 58,798,952,934.88, an increase of 11.73% from RMB 52,626,017,301.34 at the beginning of the period[4] - Shareholders' equity attributable to the company increased by 6.62% to RMB 30,508,928,111.73 from RMB 28,614,028,833.95[4] Financial Ratios - The company's debt-to-asset ratio at the end of the period was 47.92%, an increase of 2.51% from the beginning of the period[6] Factors Influencing Performance - The increase in financial metrics was attributed to new project capacity and effective cost control in raw material procurement and management[6] Audit Status - The financial data presented is preliminary and subject to change upon final audit in the annual report[8]

特别提示：本公告所载 2025 年年度主要财务数据为初步核算数据，未经会 计师事务所审计，具体数据以公司 2025 年年度报告中披露的数据为准，提请投 资者注意投资风险。 证券代码：920278 证券简称：鹿得医疗 公告编号：2026-004 江苏鹿得医疗电子股份有限公司 2025 年年度业绩快报公 告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 1、经营情况： 报告期内，公司实现营业总收入预计为 300,328,058.66 元，同比下降 12.85%； 归属于上市公司股东的净利润预计为 18,913,373.29 元，同比下降 31.33%；归属 于上市公司股东的扣除非经常性损益的净利润预计为 16,662,834.86 元，同比下 降 36.42%；基本每股收益预计为 0.11 元，同比下降 31.33%。 2、财务状况： 报告期末，公司总资产预计为 589,226,940.16 元，同比增长 11.27%；归属于 上市公司股东的所有者权益预计为 383,776,435.86 元，同比下降 4 ...

武汉微创光电股份有限公司 2025 年年度业绩快报公告 证券代码：920198 证券简称：微创光电 公告编号：2026-005 （一）报告期的经营情况、财务状况及影响经营业绩的主要因素 报告期内公司实现营业收入 17,663.00 万元，同比下降 16.20%；利润总额 -1,635.72万元，同比下降1,742.70%；归属于上市公司股东的净利润-1,170.56 万元，同比下降 384.65%；归属于上市公司股东的扣除非经常性损益的净利润 -1,312.85 万元，同比下降 439.25%；基本每股收益-0.07 元，同比下降 333.33%。 报告期末总资产 69,833.66 万元，同比下降 1.20%；归属于上市公司股东 的所有者权益 43,085.13 万元，同比下降 2.66%；归属于上市公司股东的每股 净资产 2.67 元，同比下降 2.55%。 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 特别提示：本公告所载 2025 年年度主要财务数据为初步核算数据，未经会 计师事务所审计，具体 ...